CLINICAL USE

Antibacterial agent

DOSE IN NORMAL RENAL FUNCTION

1 g every 8–12 hours

PHARMACOKINETICS

  • Molecular weight                           :319.4
  • %Protein binding                           :No data
  • %Excreted unchanged in urine     : 80–90
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :4

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Avoid. See ‘Other Information’

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Avoid. See ‘Other Information’
  • HD                     :Unknown dialysability. Avoid. See ‘Other Information’
  • HDF/high flux   :Unknown dialysability. Avoid. See ‘Other Information’
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antibacterials: increased risk of crystalluria with sulphonamides
  • Diuretics: effects antagonised by acetazolamide

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Avoid hippurate salt in renal impairment due to the risk of hippurate crystalluriaMethenamine is not recommended in severe renal impairment as urinary concentrations are too low for it to be effective

  • Contraindicated in metabolic acidosis, severe dehydration, renal parenchymal infections and hepatic failureMethenamine hippurate.
    • Tags:

    Related News

    ffddfd

    Hyperlipidemia